AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06740903
Drug: inj. dexmedetomidine infusion @ 0.2-0.4 μg/kg/h
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Anesthesia induction will be done by doing pre-oxygenation for 3 minutes with 100% oxygen, propofol 2-2.5 mg/kg intravenous (IV) and nalbuphine 0.1mg/kg intravenous (IV). Tracheal intubation will be facilitated by succinylcholine 1.5 mg/kg IV. Anaesthesia will be maintained with isoflurane 0.6 mac, 60% nitrous oxide, 40% oxygen, atracurium 0.5mg/kg bolus followed by 0.15mg/kg maintenance dose every 30 mints until completion of surgery. Patients Intraoperative monitoring will include electrocardiogram leads II and V5, non-invasive blood pressure at 5 min intervals, oxygen saturation, end-tidal carbon dioxide and nasopharyngeal temperature. Patients will be ventilated by intermittent positive pressure ventilation using a circle system to maintain normocapnia. In group A, patients will be given inj. dexmedetomidine infusion @ 0.2-0.4 μg/kg/h intraoperatively
Trial: NCT06561555
Drug: RC48
RxNorm normalized name: RC48
DrugBank: Disitamab vedotin (DB17208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RC48 at a dosage of 2mg/kg administered intravenously every 3 weeks (ivgtt q3w) is continued until disease progression, with the allowance for treatment discontinuation due to disease progression, death, intolerable toxicity, withdrawal of informed consent, initiation of new antineoplastic therapy, or other reasons specified in the protocol, with the earliest occurring event taking precedence. Alternatively, the study investigator may determine the need to discontinue treatment.
Trial: NCT05041920
Drug: famitinib、omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: famitinib malate, 25 mg on study day 1; omeprazole, 40 mg, qd on study day 10-14, 16-22; famotine malate together with omeprazole, on study day 15.
Trial: NCT06056570
Drug: dontinurad
RxNorm normalized name: Dotinurad
DrugBank: Dotinurad (DB16145)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: dotinurad alone
Trial: NCT06056570
Drug: dotinurad + allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dotinurad + allopurinol 300mg
Trial: NCT06056570
Drug: allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: allopurinol 300 mg alone
Trial: NCT06153693
Drug: lorundrostat Dose 1
RxNorm normalized name: Lorundrostat
DrugBank: Lorundrostat (DB18957)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg lorundrostat Dose 1 once daily (QD) for 12 weeks
Trial: NCT06153693
Drug: lorundrostat Dose 2
RxNorm normalized name: Lorundrostat
DrugBank: Lorundrostat (DB18957)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg lorundrostat Dose 1 once daily (QD) for 6 weeks then 100 mg lorundrostat Dose 2 once daily (QD) for 6 weeks for subjects who meet prespecified criteria
Trial: NCT04320888
Drug: Selpercatinib
RxNorm normalized name: Selpercatinib
DrugBank: Selpercatinib (DB15685)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT05972772
Drug: Doxycyclin
RxNorm normalized name: Doxycyclin
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100-mg film-coated tablets; Pfizer
Trial: NCT06341647
Drug: AB-201
RxNorm normalized name: AB-201
DrugBank: AB-201 (DB18629)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NK Cell Therapy
Trial: NCT06341647
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphodepleting chemotherapy
Trial: NCT06444451
Drug: Amlitelimab
RxNorm normalized name: Amlitelimab
DrugBank: Amlitelimab (DB18835)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Injection solution Route of administration: SC injection
Trial: NCT06772597
Drug: Setmelanotide
RxNorm normalized name: Setmelanotide
DrugBank: Setmelanotide (DB11700)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Setmelanotide (daily subcutaneous injection)
Trial: NCT06004245
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab will be administered by intravenous (IV) infusion at a fixed dose of 200 mg on Day 1 of each 21-day cycle.
Trial: NCT06772727
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After preoxygenation with 100% oxygen for 3 minutes, the study drug (lidocaine) will be administered. Patients will receive 1 mg/kg lidocaine of 10 mg/mL lidocaine solution (prepared by diluting 5 mL of lidocaine 20% in saline to a total volume of 10 mL)
Trial: NCT06772727
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After administration of the study drug, all patients will receive 2 mg/kg propofol intravenously
Trial: NCT06775080
Drug: propranolol (beta-blocker used treat high blood pressure)
RxNorm normalized name: beta-Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enrolled patients began receiving propranolol alone orally twice daily (10 mg bid) 10-14 days prior to surgery, and after 3 days of treatment, the dose of propranolol was increased to 20 mg bid daily until the day of surgery if the following three predefined criteria were met: systolic blood pressure greater than 90 mmHg, heart rate greater than 60 bpm, and no significant symptoms (e.g., syncope, insomnia, fatigue). The patient continues to be treated from 1 week after surgery.From 1 week after surgery, patients continue propranolol for 3 weeks. Patients will be monitored daily for symptoms, blood pressure, and heart rate and will be followed for observation at 6, 12, and 24 months after surgery until disease progression or clinical death, unless intolerable toxicity occurs and the patient refuses to continue treatment. The efficacy and safety of the preoperative propranolol β-blockade regimen in patients with gastrointestinal tract tumors was evaluated using the study objectives in S
Trial: NCT06111885
Drug: Hydrochlorothiazide 50Mg
RxNorm normalized name: HYDROCHLOROTHIAZIDE 50MG TAB
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 hydrochlorothiazide 50 mg capsule per day for 28 days
Trial: NCT06748001
Drug: Avapritinib
RxNorm normalized name: Avapritinib
DrugBank: Avapritinib (DB15233)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Avapritinib will be administered in accordance with the parent study protocol.
Trial: NCT06746558
Drug: Potassium Nitrate Gel Alone
RxNorm normalized name: Potassium Nitrate
DrugBank: Potassium citrate (DB09125)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants in the control group receive treatment with a desensitizing gel containing 5% potassium nitrate (Emoform Actisens) applied to the teeth. The gel is applied twice using a microbrush in a rubbing motion for 2 minutes each time. No diode laser therapy is administered. This intervention aims to evaluate the standalone efficacy of the gel in reducing dentinal hypersensitivity.
Trial: NCT06732531
Drug: BH011
RxNorm normalized name: Buprenorphine Hydrochloride
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BH011 is administered intravesically through a urinary catheter and is retained in the bladder for 1 hour. It was administered once a week for 6 weeks during the induction treatment period and once a month for 12 months during the maintenance treatment period.
Trial: NCT06760676
Drug: Alpaloritovorelli antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PLDR external irradiation therapy was administered simultaneously with 5mg/kg Alpaloritovorelli antibodies for a 3-week regimen, the following maintenance treatment was 2 years.
Trial: NCT06786299
Drug: CD84-CART
RxNorm normalized name: prilocaine
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy
Trial: NCT05695339
Drug: Resiniferatoxin
RxNorm normalized name: resiniferatoxin
DrugBank: Resiniferatoxin (DB06515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An injection of 1-2 ml bupivacaine 0.5% will be placed around the affected branch of the neuroma (aiming at its proximal end) and dorsal adjacent tissue including the skin dorsally to the neuroma. This is to prevent pain caused by any microscopic spills of RTX during the. A second local anesthetic depot will be placed 1-2 cm proximally to the injection site around the affected branch of the plantar nerve to prevent pain caused by passive current transmission by axonal RTX excitation. Following the course of the affected nerve branch and ultra-sound visualization of the injection site, 0.5-2 ml bupivacaine 0.5% will be injected perineurally. Once the site has sufficient nerve block, the required RTX dose in a solution of 0.25 ml will be injected directly proximal to the Morton s neuroma under ultra-sound visualization.
Trial: NCT05530421
Drug: Selinexor
RxNorm normalized name: Selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Selinexor tablets will be administered orally (PO) once per day at assigned dosage and frequency per protocol.
Trial: NCT05530421
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Venetoclax tablets will be administered orally (PO) once per day at assigned dosage and frequency per protocol.
Trial: NCT05530421
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone tablets will be administered orally (PO) once per day at assigned dosage and frequency per protocol.
Trial: NCT04929028
Drug: Mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05645523
Drug: Indocyanine Green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given in to the vein (IV)
Trial: NCT06791083
Drug: Envafolimab
RxNorm normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg/m2 , IH， d1；Q3W
Trial: NCT06791083
Drug: Fruquintinib
RxNorm normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg ，po，QD，d1-d14；Q3W
Trial: NCT06768294
Drug: Baricitinib 4 MG Oral Tablet
RxNorm normalized name: Baricitinib 4 mg oral tablet
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Baricitinib is a JAK1/JAK2 inhibitor approved for use in Rheumatoid Arthritis. It is under investigation for use in several inflammatory diseases, including Psoriasis and Psoriatic Arthritis, Atopic Dermatitis, Inflammatory Bowel Disease and Systemic Lupus Erythematosus, with encouraging results. As IL-6 plays a central role in CPPD inflammatory process, a broad spectrum of interleukins and other proinflammatory proteins (including interferons) could be involved. A drug that acts by blocking more than one proinflammatory cytokine could be a promising treatment for a multifaceted disease such as CPPD.
Trial: NCT06768294
Drug: Methylprednisolone (Corticosteroid)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The initial dosage of methylprednisolone may vary depending on the entity of inflammation and the patient's comorbidities. Usually in CPPD a short-term administration of methylprednisolone starts with 16 mg per day after breakfast decreasing the initial dosage in small decrements at appropriate time intervals until discontinuation, in about 2 weeks. Methylprednisolone will be given in combination with gastroprotective agents such as proton pump inhibitors.
Trial: NCT06768294
Drug: Colchicine 1 MG Oral Tablet
RxNorm normalized name: colchicine 1 MG Oral Tablet
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 or ½ tablet (depending on individual tolerance) daily after breakfast
Trial: NCT06768294
Drug: Hydroxychloroquine 200 mg
RxNorm normalized name: hydroxychloroquine 200 mg oral tablet
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet daily after lunch
Trial: NCT06773208
Drug: Azacitidine (AZC)
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 75 mg/m2 daily, on days 1-7, given IV or SC
Trial: NCT06773208
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Venetoclax 400 mg orally daily on days 1-28
Trial: NCT06623370
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will undergo standard noninvasive blood pressure monitoring, electrocardiogram, peripheral oxygen saturation (SpO2), and capnography. After anesthesia induction, neuromuscular monitoring will also be applied. Anesthesia induction will be performed with 2-4 mg/kg propofol and 1 mcg/kg fentanyl. First group (Group M), patients will receive 1 mg/kg methylprednisolone , while in the second group (Group C), patients will receive 5 ml of normal saline. Immediately afterward, the neuromuscular monitor will be set to measure the Train of Four (TOF). Following this, 0.6-1.2 mg/kg of rocuronium will be administered intravenously. If necessary, additional doses of 0.15 mg/kg rocuronium will be given during the operation when TOF count reaches T2. For postoperative analgesia, 15 mg/kg of i.v. paracetamol will be administered. At the end of the surgery, when anesthesia is terminated and T2 reappears in TOF count, all patients will receive a single bolus injection of sugammadex.
Trial: NCT04305327
Drug: Brodalumab
RxNorm normalized name: Brodalumab
DrugBank: Brodalumab (DB11776)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Solution for subcutaneous injection.
Trial: NCT04305327
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Solution for subcutaneous injection.
Trial: NCT06745726
Drug: Zestril
RxNorm normalized name: Zestril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N/A, this is an observational study.
Trial: NCT06778395
Drug: Dexlansoprazole 60 mg
RxNorm normalized name: dexlansoprazole 60 MG
DrugBank: Dexlansoprazole (DB05351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: once daily for 8 weeks
Trial: NCT06778395
Drug: Vonoprazan 20 mg bid
RxNorm normalized name: vonoprazan 20 MG
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: twice daily for 8 weeks
Trial: NCT06716424
Drug: iGlarLixi (insulin glargine/lixisenatide)
RxNorm normalized name: INSULIN GLARGINE/LIXISENATIDE
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: iGlarLixi is available as a sterile solution for injection that will be administered to study participants subcutaneously
Trial: NCT06124209
Drug: TachoSil
RxNorm normalized name: TachoSil
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TachoSil used in Vena Cava Inferior anastomosis during liver transplantation.
Trial: NCT06746831
Drug: S-(+)-methamphetamine
DrugBank: Amphetamine (DB00182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg
Trial: NCT06746831
Drug: R-(-)-methamphetamine
DrugBank: Amphetamine (DB00182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg
Trial: NCT04643574
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine will be administered as an intravenous (IV) infusion for five days.
Trial: NCT04643574
Drug: Interleukin-2
RxNorm normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of fourteen doses.
Trial: NCT06582420
Drug: Fibrinogen concentrate
RxNorm normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomly assigned to receive either standard trauma care or standard trauma care plus administration of FC. The standard of care is determined by national guidelines on trauma, elaborated by the National Institute of Medical Emergency and taught to prehospital physicians and nurses at the time of enrollment in prehospital teams to ensure consistency in the treatment of trauma patients nationwide. The patients assigned to the intervention arm will receive the administration of a fixed dose of 4g fibrinogen, as per previous studies.
Trial: NCT06775366
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam 6mg/kg/h was pumped intravenously for 2.5 min, Sufentanil 0.5 μg/kg and rocuronium 0.6mg/kg were injected intravenously, and endotracheal intubation was performed 3 minutes later. Remimazolam was then pumped at 1 mg/kg/h, the BIS was kept in the range of 40-60 through general anesthesia, and the remimazolam infusion rate was adjusted (0.5-3 mg/kg/h).If the BIS cannot be maintained at ≤ 60 or there are signs of potential inadequate anesthesia (such as cough, sweating, and patient movement), and the maximum infusion dose of remimazolam has been given, supplemental sedation with the remedial drug sevoflurane or propofol is used and the case is dismissed.
Trial: NCT06775366
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol (2-3mg/kg), Sufentanil (0.5μg /kg), rocuronium (0.6mg/kg) were injected intravenously, and endotracheal intubation was performed for 3 minutes. Subsequently, propofol was pumped at 4-10mg/kg/h to maintain the BIS in the range of 40-60.
Trial: NCT06756321
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine will be given at a dose of 25 mg/m\^2/day intravenously (IV) for 3 days prior to the infusion of CAR T-cells.
Trial: NCT04551131
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally (PO) or per nasogastric tube (NGT) twice a day for 8 weeks
Trial: NCT04551131
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intravenously (IV) or orally (PO) twice a day for 8 weeks
Trial: NCT04551131
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intravenously (IV) once a week for 8 weeks
Trial: NCT06753994
Drug: SGLT-2 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Empagliflozin is an SGLT2i that aids in blood glucose reduction through the urination of excess glucose in the context of hyperglycemia. In this study, participants will start with a dose of 2.5 mg of empagliflozin for four weeks, which will then be increased to 10 mg for the following nine weeks.
Trial: NCT06751901
Drug: PD-1 inhibitor
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with PD-1 inhibitors will begin after the completion of radiotherapy, with a treatment cycle of 3 weeks. On the first day (D1) of each treatment cycle, the drug is administered intravenously, with the dosage according to the instructions.
Trial: NCT06754540
Drug: Azacitidine (AZA)
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine 32mg/m2
Trial: NCT06782555
Drug: Evofosfamide
RxNorm normalized name: Evofosfamide
DrugBank: Evofosfamide (DB06091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evofosfamide administered on Days 1 and 8 of Cycles 1, 2, and 3.
Trial: NCT06782555
Drug: Zalifrelimab
RxNorm normalized name: Zalifrelimab
DrugBank: Zalifrelimab (DB15632)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zalifrelimab administered on Day 8 of Cycles 1, 3, and 5.
Trial: NCT06782555
Drug: Balstilimab
RxNorm normalized name: Balstilimab
DrugBank: Balstilimab (DB15676)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balstilimab administered every 2 weeks beginning on Day 8 of Cycle 1.
Trial: NCT05700214
Drug: Ropivacaine injection
RxNorm normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30ml of 0.375% ropivacaine
Trial: NCT05700214
Drug: Lidocaine IV
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Before induction bolus of 1% lidocaine 1,5mg/kg IBW i.v., continuous infusion of 1% lidocaine intraoperatively rate 1 mg/kg IBW i.v.
Trial: NCT06426537
Drug: Colchicine 0.5 MG Oral Tablet
RxNorm normalized name: colchicine 0.5 mg oral tablet
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Colchicine in STEMI patients
Trial: NCT00408473
Drug: Flecainide
RxNorm normalized name: Flecainide
DrugBank: Flecainide (DB01195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05480150
Drug: Escitalopram Oxalate Tablets
RxNorm normalized name: Escitalopram Oxalate
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting at 5mg qn, the treatment dose was titrated to 10-20mg qn within 1 week and maintained for 4 weeks
Trial: NCT05480150
Drug: Quetiapine Fumarate Tablets
RxNorm normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting at 50mg qn, the treatment dose was titrated to 300-400mg qn within 10 days, and maintained the treatment for 4 weeks.
Trial: NCT05480150
Drug: Lurasidone
RxNorm normalized name: Lurasidone
DrugBank: Lurasidone (DB08815)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Starting at 20mg qn, the treatment dose was titrated to 40mg qn within 6 days,and maintained the treatment for 4 weeks.